Dr. Maija Wolf, Ph.D., is a Senior Researcher at FIMM focusing on the development of advanced leukemia assays and managing collaborative pharma projects. Maija Wolf has a solid background in cancer biology and molecular profiling, and her main career objectives have involved resolving how cancer evolves and identifying novel therapeutic opportunities. She received her Ph.D. in 2000 (molecular genetic studies on human sarcomas) after which she continued her studies on functional cancer genomics at the NHGRI, NIH, Maryland, USA and later at the VTT Medical Biotechnology, Turku. In 2008 Maija Wolf joined FIMM where her current scientific focus is on hematological malignancies, particularly acute myelogenous leukemia, and the potential of precision medicine. She is also actively managing collaborative projects with pharma industry.
Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JML, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K. Individualized Systems Medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discovery 2013; 3:1416-1429. IF: 15.929
Edgren H, Murumägi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale A-L, Kallioniemi O. Identification of fusion genes in breast cancer by paired-end-sequencing. Genome Biol 2011;19;12(1):R6. IF: 10.465
Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, Pisto T, Saarela M, Skotheim RI, Björkman M, Mpindi J-P, Haapa-Paananen S, Vainio P, Edgren H, Wolf M, Astola J, Nees M, Hautaniemi S, Kallioniemi O. Systematic bioinformatic analysis of expression levels of 17330 human genes across 9783 samples from 175 types of healthy and pathological tissues. Genome Biology 2008; 9(9):R139. IF: 10.465
Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim R, Peltola M, Smit F, Verhaegh G, Schalken J, Nees M, Kallioniemi O. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006; 66(21):10242-10246. IF: 9.284
Huusko P, Ponciano-Jackson D, Wolf M, Kiefer J, Azorsa D, Tuzmen S, Weaver D, Robbins C, Moses T, Allinen M, Hautaniemi S, Chen Y, Elkahloun A, Basik M, Bova GS, Bubendorf L, Lugli A, Sauter G, Schleutker J, Ozcelik H, Elowe S, Pawson T, Trent J, Carpten J, Kallioniemi O-P, Mousses S. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nature Genet 2004; 36:979-983. IF: 29.648